Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Wilkens MK"'
Autor:
Chand D; Agenus (United States), Lexington, MA, United States., Savitsky DA; Agenus, Lexington, MA, United States., Krishnan S; Agenus (United States), Lexington, MA, United States., Mednick G; Agenus (United States), Lexington, MA, United States., Delepine C; Agenus (United States), Lexington, MA, United States., Garcia-Broncano P; Agenus (United States), Lexington, MA, United States., Soh KT; Agenus (United States), Lexington, MA, United States., Wu W; Agenus (United States), Lexington, MA, United States., Wilkens MK; Agenus (United States), Lexington, MA, United States., Udartseva O; Agenus (United States), Lexington, MA, United States., Vincent S; Agenus (United States), Lexington, MA, United States., Joshi B; Agenus (United States), Lexington, MA, United States., Keith JG; Agenus (United States), Lexington, MA, United States., Manrique M; Agenus (United States), Lexington, MA, United States., Marques M; Agenus (United States), Lexington, MA, United States., Tanne A; Agenus (United States), Lexington, MA, United States., Levey DL; Agenus (United States), Lexington, MA, United States., Han H; Translational Genomics Research Institute, Phoenix, AZ, United States., Ng S; TGEN, Phoenix, Arizona, United States., Ridpath J; Agenus (United States), Lexington, MA, United States., Huber O; Agenus (United States), Lexington, MA, United States., Morin B; Agenus Inc., Lexington, MA, United States., Galand C; Agenus (United States), Lexington, MA, United States., Bourdelais S; Agenus (United States), Lexington, MA, United States., Gombos RB; Agenus Inc., Lexington, MA, United States., Ward R; Agenus Inc, Lexington, MA, United States., Qin Y; Agenus (United States), Lexington, MA, United States., Waight JD; GlaxoSmithKline (United States), Collegeville, PA, United States., Costa MR; Agenus (United States), Lexington, MA, United States., Sebastian-Yague A; Agenus (United States), Cambridge, United Kingdom., Rudqvist NP; Agenus (United States), Lexington, MA, United States., Pupecka-Swider M; Agenus (United States), Cambridge, United Kingdom., Venkatraman V; Agenus (United States), Cambridge, United Kingdom., Slee A; Agenus (United States), Lexington, MA, United States., Patel JM; Agenus (United States), Lexington, MA, United States., Grossman JE; Agenus Inc., Lexington, MA, United States., Wilson NS; Agenus Inc., Lexington, MA, United States., Von Hoff DD; Translational Genomics Research Institute, Phoenix, United States., Stebbing J; Anglia Ruskin University, Cambridge, United Kingdom., Curiel TJ; Dartmouth Health and The Geisel Medical School at Dartmouth, Lebanon, NO, United States., Buell JS; Agenus Inc., Lexington, MA, United States., O'Day SJ; Agenus Inc., Lexington, MA, United States., Stein RB; Agenus (United States), Lexington, MA, United States.
Publikováno v:
Cancer discovery [Cancer Discov] 2024 Jul 31. Date of Electronic Publication: 2024 Jul 31.
Autor:
Köhler J; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts. pasi_janne@dfci.harvard.edu jens_kohler@dfci.harvard.edu., Zhao Y; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., Li J; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., Gokhale PC; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Tiv HL; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Knott AR; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Wilkens MK; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Soroko KM; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Lin M; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., Ambrogio C; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.; Department of Molecular Biotechnology and Health Science, Molecular Biotechnology Center, University of Torino, Torino, Italy., Musteanu M; Experimental Oncology, Molecular Oncology Program, CNIO, Madrid, Spain.; Biochemistry and Molecular Biology Department, Faculty of Pharmacy, Complutense University of Madrid, Spain., Ogino A; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., Choi J; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., Bahcall M; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., Bertram AA; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., Chambers ES; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., Paweletz CP; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Bhagwat SV; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana., Manro JR; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana., Tiu RV; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana., Jänne PA; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts. pasi_janne@dfci.harvard.edu jens_kohler@dfci.harvard.edu.; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Publikováno v:
Molecular cancer therapeutics [Mol Cancer Ther] 2021 Apr; Vol. 20 (4), pp. 641-654. Date of Electronic Publication: 2021 Feb 03.
Autor:
Iorgulescu JB; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts., Gokhale PC; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Speranza MC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Eschle BK; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Poitras MJ; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Wilkens MK; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Soroko KM; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Chhoeu C; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Knott A; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Gao Y; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Lim-Fat MJ; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Baker GJ; Department of Systems Biology, Harvard Medical School, Boston, Massachusetts., Bonal DM; Lurie Family Imaging Center, Dana-Farber Cancer Institute, Boston, Massachusetts., Nguyen QD; Lurie Family Imaging Center, Dana-Farber Cancer Institute, Boston, Massachusetts., Grant GRL; University of Glasgow Medical School, Glasgow, Scotland, United Kingdom., Ligon KL; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts.; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Broad Institute of Harvard and MIT, Cambridge, Massachusetts., Sorger PK; Department of Systems Biology, Harvard Medical School, Boston, Massachusetts., Chiocca EA; Department of Neurosurgery, Brigham and Women's Hospital, Boston, Massachusetts., Anderson AC; Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts.; Department of Immunology, Blavatnik Institute, Harvard Medical School and Evergrande Center for Immunologic Diseases, Harvard Medical School, Boston, Massachusetts., Kirschmeier PT; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Sharpe AH; Department of Immunology, Blavatnik Institute, Harvard Medical School and Evergrande Center for Immunologic Diseases, Harvard Medical School, Boston, Massachusetts., Freeman GJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Reardon DA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. david_reardon@dfci.harvard.edu.; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2021 Jan 01; Vol. 27 (1), pp. 276-287. Date of Electronic Publication: 2020 Nov 25.
Autor:
Ogino A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Choi J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Lin M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Wilkens MK; Experimental Therapeutics Core, Dana-Farber Cancer Institute, Boston, MA, USA., Calles A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Xu M; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA, USA., Adeni AE; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Chambers ES; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Capelletti M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Butaney M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Gray NS; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA., Gokhale PC; Experimental Therapeutics Core, Dana-Farber Cancer Institute, Boston, MA, USA., Palakurthi S; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA, USA., Kirschmeier P; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA, USA., Oxnard GR; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Sholl LM; Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA., Jänne PA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA, USA.; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Publikováno v:
Molecular oncology [Mol Oncol] 2021 Jan; Vol. 15 (1), pp. 27-42. Date of Electronic Publication: 2020 Nov 25.
Autor:
Morrison-Smith CD; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts., Knox TM; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts., Filic I; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts., Soroko KM; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Eschle BK; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Wilkens MK; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Gokhale PC; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Giles F; Developmental Therapeutics Consortium, Chicago, Ilinois., Griffin A; Praxis Precision Medicines, Cambridge, Massachusetts., Brown B; Paraza Pharma Inc., Montreal, Quebec, Canada., Shapiro GI; Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Zucconi BE; Department of Medicine, Division of Genetics, Brigham and Women's Hospital and Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts., Cole PA; Department of Medicine, Division of Genetics, Brigham and Women's Hospital and Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts., Lemieux ME; Bioinfo, Plantagenet, Ontario, Canada., French CA; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. cfrench@bwh.harvard.edu.
Publikováno v:
Molecular cancer therapeutics [Mol Cancer Ther] 2020 Jul; Vol. 19 (7), pp. 1406-1414. Date of Electronic Publication: 2020 May 05.
Autor:
Kurppa KJ; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA., Liu Y; Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02215, USA., To C; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA., Zhang T; Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02215, USA., Fan M; Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02215, USA., Vajdi A; Department of Informatics and Analytics, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Knelson EH; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA., Xie Y; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Lim K; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Cejas P; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Portell A; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Lizotte PH; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Ficarro SB; Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA; Blais Proteomics Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02215, USA., Li S; Division of Hematology & Medical Oncology, Laura and Isaac Perlmutter Cancer Center, New York University Langone Medical Center, New York, NY, USA., Chen T; Division of Hematology & Medical Oncology, Laura and Isaac Perlmutter Cancer Center, New York University Langone Medical Center, New York, NY, USA., Haikala HM; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA., Wang H; School of Life Science and Technology, Tongji University, 200092 Shanghai, China., Bahcall M; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA., Gao Y; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Pediatrics, Harvard Medical School, Boston, MA 02215, USA., Shalhout S; Stem Cell Program, Boston Children's Hospital, Boston, MA 02215, USA; Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA., Boettcher S; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., Shin BH; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA., Thai T; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA., Wilkens MK; Experimental Therapeutics Core, Dana-Farber Cancer Institute, Boston, MA 02210, USA., Tillgren ML; Experimental Therapeutics Core, Dana-Farber Cancer Institute, Boston, MA 02210, USA., Mushajiang M; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA., Xu M; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Choi J; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA., Bertram AA; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA., Ebert BL; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Howard Hughes Medical Institute, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Beroukhim R; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA., Bandopadhayay P; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA 02115, USA., Awad MM; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA., Gokhale PC; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Experimental Therapeutics Core, Dana-Farber Cancer Institute, Boston, MA 02210, USA., Kirschmeier PT; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Marto JA; Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA; Blais Proteomics Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02215, USA., Camargo FD; Stem Cell Program, Boston Children's Hospital, Boston, MA 02215, USA; Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA., Haq R; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA; Department of Molecular and Cellular Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Paweletz CP; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Wong KK; Division of Hematology & Medical Oncology, Laura and Isaac Perlmutter Cancer Center, New York University Langone Medical Center, New York, NY, USA., Barbie DA; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA., Long HW; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Gray NS; Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02215, USA., Jänne PA; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, LC4114, Boston, MA 02215, USA. Electronic address: pasi_janne@dfci.harvard.edu.
Publikováno v:
Cancer cell [Cancer Cell] 2020 Jan 13; Vol. 37 (1), pp. 104-122.e12.